ALHEMO (concizumab)

TherapyNovo Nordisk

ALHEMO (concizumab) from Novo Nordisk is a therapy engineered for use in hemophilia settings, including patients with inhibitors.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and ALHEMO. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where ALHEMO is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors Non-cancer · Blood	Concizumab Tissue factor pathway inhibitor antagonist		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for ALHEMO.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering ALHEMO for eligible patients.

Test

ConcizuTrace ELISA

Randox Laboratories Ltd.

Method

ELISA

Specimen

Plasma

1 approvalView test profile →

This view is scoped to ALHEMO (concizumab). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.